Form 4: Exagen Inc. CEO John Aballi Sells 24,305 Shares

Exagen Inc.'s CEO, John Aballi, sold 24,305 shares of common stock at an average price of $2.81 per share on November 14, 2024.

Summary

• John Aballi, the President and CEO of Exagen Inc., sold 24,305 shares of common stock on November 14, 2024.
• The shares were sold at a weighted average price of $2.81 per share.
• The sale was executed in multiple transactions with prices ranging from $2.72 to $2.94 per share.
• Following the transaction, Mr. Aballi directly owns 689,799 shares of Exagen Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing for insider trading activity, which is neither positive nor negative in itself. The sale of shares by the CEO is a neutral event.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The sale of shares by a CEO is not unusual, and the volume of shares sold is not significant enough to indicate a major shift in the company's outlook.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on investor sentiment, but it is unlikely to significantly affect the company's operations or financial performance.

Key Dates

Keywords

Exagen Inc., John Aballi, stock sale, insider trading, common stock, SEC Form 4